Przeglad lekarski, 53(9), 666-667 (1996-01-01)
Glipizide is a second generation of sulphonylurea compound, effective in lowering of blood glucose, well-tolerated as well as safe during long-term treatment. Glipizide is the agent characterized by rapid pharmacological action. It is indicated both in monotherapy and combined treatment...
R H Foster et al.
PharmacoEconomics, 18(3), 289-306 (2001-01-09)
Glipizide is a second generation sulphonylurea agent that is available in a Gastrointestinal Therapeutic System (GITS) extended-release formulation. Glipizide GITS provides more stable plasma drug concentrations than the immediate-release formulation and the once-daily regimen may optimise patient compliance. In patients...
[The clinical pharmacology of Minidiab (glipizide) (a review of the literature)].
A V Shcherbak
Likars'ka sprava, (1)(1), 28-33 (1993-01-01)
S L Ford
The Veterinary clinics of North America. Small animal practice, 25(3), 599-615 (1995-05-01)
The oral hypoglycemic medication, glipizide, provides a viable therapeutic alternative to conventional insulin therapy with a positive therapeutic response in approximately 50% of diabetic cats with non-insulin-dependent disease. Response to glipizide therapy or lack thereof usually is evident within the...
R N Brogden et al.
Drugs, 18(5), 329-353 (1979-11-01)
Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide....